A phase IV, open-label, prospective observational study to evaluate virological response in antiretroviral-experienced hiv 1 infected subjects switching to Atripla (efavirenz/emtricitabine/tenofovir DF) on an empty stomach.

Trial Profile

A phase IV, open-label, prospective observational study to evaluate virological response in antiretroviral-experienced hiv 1 infected subjects switching to Atripla (efavirenz/emtricitabine/tenofovir DF) on an empty stomach.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms ONCE
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Nov 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 18 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top